Librería: GreatBookPrices, Columbia, MD, Estados Unidos de America
EUR 48,31
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New.
Librería: BargainBookStores, Grand Rapids, MI, Estados Unidos de America
EUR 50,67
Cantidad disponible: 5 disponibles
Añadir al carritoHardback or Cased Book. Condición: New. Headache Disorders: New Advances in Management and Treatment Strategies. Book.
Librería: California Books, Miami, FL, Estados Unidos de America
EUR 52,71
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New.
Librería: GreatBookPrices, Columbia, MD, Estados Unidos de America
EUR 52,49
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: As New. Unread book in perfect condition.
Librería: Rarewaves USA, OSWEGO, IL, Estados Unidos de America
EUR 58,89
Cantidad disponible: Más de 20 disponibles
Añadir al carritoPaperback. Condición: New.
Librería: Rarewaves.com USA, London, LONDO, Reino Unido
EUR 65,03
Cantidad disponible: Más de 20 disponibles
Añadir al carritoPaperback. Condición: New.
Librería: GreatBookPricesUK, Woodford Green, Reino Unido
EUR 51,85
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New.
Librería: GreatBookPricesUK, Woodford Green, Reino Unido
EUR 58,69
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: As New. Unread book in perfect condition.
Librería: Rarewaves USA United, OSWEGO, IL, Estados Unidos de America
EUR 60,62
Cantidad disponible: Más de 20 disponibles
Añadir al carritoPaperback. Condición: New.
Librería: Rarewaves.com UK, London, Reino Unido
EUR 60,24
Cantidad disponible: Más de 20 disponibles
Añadir al carritoPaperback. Condición: New.
Librería: PBShop.store US, Wood Dale, IL, Estados Unidos de America
EUR 55,34
Cantidad disponible: Más de 20 disponibles
Añadir al carritoHRD. Condición: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.
Librería: PBShop.store UK, Fairford, GLOS, Reino Unido
EUR 51,86
Cantidad disponible: Más de 20 disponibles
Añadir al carritoHRD. Condición: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.
Librería: Majestic Books, Hounslow, Reino Unido
EUR 53,07
Cantidad disponible: 4 disponibles
Añadir al carritoCondición: New. Print on Demand.
Librería: Books Puddle, New York, NY, Estados Unidos de America
EUR 60,07
Cantidad disponible: 4 disponibles
Añadir al carritoCondición: New. Print on Demand.
Librería: Biblios, Frankfurt am main, HESSE, Alemania
EUR 53,62
Cantidad disponible: 4 disponibles
Añadir al carritoCondición: New. PRINT ON DEMAND.
Librería: CitiRetail, Stevenage, Reino Unido
EUR 58,95
Cantidad disponible: 1 disponibles
Añadir al carritoHardcover. Condición: new. Hardcover. Four anti-CGRP MAbs are currently in use for the prevention of episodic and chronic migraine: erenumab, which targets the CGRP receptor, and fremanezumab, galcanezumab, and eptinezumab, which target the CGRP ligand. In addition, anti-CGRP MAbs have shown some degree of success as preventive treatments for other headache disorders, such as cluster and post-traumatic headaches. There are, however, unmet needs associated with the prophylactic management of these headache disorders, because of inadequate headache frequency reduction in about one-third of migraine patients and an even higher percentage of treatment failure in cluster and post-traumatic headache patients. Significant unmet needs are also present in the symptomatic management of these headache disorders. To overcome these challenges, new acute pharmacological options for headaches have been studied in the last few years, including gepants, a class of small molecules that target the CGRP receptor, and ditans, a class of non-triptan serotonin receptor antagonists. Gepants have been also explored for migraine prevention. This Special Issue summarizes our existing knowledge on the advantages and limitations of modern therapies for headache disorders, highlights open clinical and pathogenetic issues, and explores future directions for research. The Co-Editors and I are confident that it will serve as a reference point for those seeking to understand why, when, and how to treat headache patients with monoclonal antibodies that target CGRP, gepants or ditans. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.
Librería: AHA-BUCH GmbH, Einbeck, Alemania
EUR 57,04
Cantidad disponible: 2 disponibles
Añadir al carritoBuch. Condición: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Four anti-CGRP MAbs are currently in use for the prevention of episodic and chronic migraine: erenumab, which targets the CGRP receptor, and fremanezumab, galcanezumab, and eptinezumab, which target the CGRP ligand. In addition, anti-CGRP MAbs have shown some degree of success as preventive treatments for other headache disorders, such as cluster and post-traumatic headaches. There are, however, unmet needs associated with the prophylactic management of these headache disorders, because of inadequate headache frequency reduction in about one-third of migraine patients and an even higher percentage of treatment failure in cluster and post-traumatic headache patients. Significant unmet needs are also present in the symptomatic management of these headache disorders. To overcome these challenges, new acute pharmacological options for headaches have been studied in the last few years, including gepants, a class of small molecules that target the CGRP receptor, and ditans, a class of non-triptan serotonin receptor antagonists. Gepants have been also explored for migraine prevention. This Special Issue summarizes our existing knowledge on the advantages and limitations of modern therapies for headache disorders, highlights open clinical and pathogenetic issues, and explores future directions for research. The Co-Editors and I are confident that it will serve as a reference point for those seeking to understand why, when, and how to treat headache patients with monoclonal antibodies that target CGRP, gepants or ditans.
Librería: preigu, Osnabrück, Alemania
EUR 65,65
Cantidad disponible: 5 disponibles
Añadir al carritoBuch. Condición: Neu. Headache Disorders | New Advances in Management and Treatment Strategies | Buch | Englisch | 2025 | MDPI AG | EAN 9783725843473 | Verantwortliche Person für die EU: Libri GmbH, Europaallee 1, 36244 Bad Hersfeld, gpsr[at]libri[dot]de | Anbieter: preigu Print on Demand.